Skip to main content
Premium Trial:

Request an Annual Quote

Bayer, Veracyte to Identify Therapy-Resistant Thyroid Cancer Patients

NEW YORK – Veracyte said on Tuesday that it has partnered with Bayer to launch the Precision Oncology Patient Identification Program in thyroid cancer, which will focus on identifying patients who may benefit from biomarker-driven therapies.

As part of the collaboration, Bayer will offer Veracyte's Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, in tumors of late-stage or metastatic patients. Bayer will provide testing at no cost to all eligible patients when ordered by their physician, regardless of their final results and treatment decisions.

South San Francisco-based Veracyte's Afirma XA uses RNA whole-transcriptome sequencing to identify 905 DNA variants and 235 RNA fusions in 593 genes on fine needle aspirate samples extracted from thyroid nodules or lymph nodes.

The companies expect to launch the program in the first quarter of 2021.

"Our collaboration with Bayer will help ensure that all eligible thyroid cancer patients can be tested and identified for actionable genomic alterations — at no cost to them — so they may potentially benefit from biomarker-driven therapies," Bonnie Anderson, CEO and chairman of Veracyte, said in a statement. "This is the first collaboration between the two companies, and we anticipate continued strategic programs to further precision oncology."

Financial details of the agreement were not disclosed.

"Patients whose thyroid cancer contains actionable alterations and no longer responds to traditional radioactive iodine therapy now have targeted treatment options available to them," Bhavesh Ashar, senior VP and head of US oncology at Bayer, said in a statement. "Our goal is to identify such patients so physicians can make more informed treatment decisions for their patients."

Bayer currently markets larotrectinib (Vitrakvi), which is approved for all refractory solid tumors with NTRK gene fusions. 

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.